Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
ResearchConsumer Staples, Technology, Healthcare
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchConsumer Discretionary, Consumer Staples, Industrials
Tech for Global, Globalization Footprints of the Established and the New
Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
Since the outbreak of COVID-19, new public health systems and advanced biotechnology have been swiftly hyped up. Genetron Health has been able to generate a surging revenue in these special social circumstances.
May 26, 2021 05:17 AM
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM